Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesUrologyAspirus Arise Adstiladrin Coverage Update | OpenPa…
    Ask Trek AI about this page
    CurrentAspirus ArisePolicy N/A

    Adstiladrin (nadofaragene firadenovec) intravesical therapy — Coverage Criteria

    Customize your policy alerts

    Sign up for all Aspirus Arise policy alerts

    Know when Aspirus Arise releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior-authorization and coverage criteria for Adstiladrin for adults with high-risk BCG-unresponsive non‑muscle invasive bladder cancer (NMIBC) with CIS with or without papillary tumors, for Aspirus Arise plans.

    Policy Summary
    PayerAspirus Arise
    PolicyAdstiladrin (nadofaragene firadenovec) intravesical therapy — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeMaterial revisions to approval duration and prescriber requirement
    Effective DateNov 15, 2023
    Last ReviewApr 8, 2026
    Next Review DateApr 8, 2026
    Key ActionObtain prior authorization and ensure Adstiladrin is prescribed by or in consultation with a urologist or oncologist.
    SourceLink
    POLICY UPDATE CHANGES

    Approval duration language changed to 'approve for the duration noted' and initial therapy approval set to 4 months to allow 2 doses (3 months apart).

    Added requirement that Adstiladrin be prescribed by or in consultation with a urologist or oncologist.

    Reworded indication option to 'Patient has Ta/T1 papillary tumors without CIS.'

    4 moinitial therapy approval duration
    3 mocontinuation approval duration
    Every 3 mo

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    dosing interval
    75 mLdose volume
    ≥18minimum age

    Recommended Authorization Criteria

    FDA-Approved Indication: Non-Muscle Invasive Bladder Cancer

    Approve for the duration noted if the patient meets ONE of the following (A or B):

    Main: Patient meets A (Initial Therapy) OR B (Currently Receiving Adstiladrin)
    A: Initial Therapy: Approve for 4 months to allow 2 doses (3 months apart) if ALL of the following are met
    A.i Age: Patient is >= 18 years of age>= 18 years
    A.ii Disease status: Patient has high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive disease
    A.iii Tumor type: Patient meets ONE: (a) carcinoma in situ (CIS) OR (b) Ta/T1 papillary tumors without CIS
    A.iv Prescriber: The medication is prescribed by or in consultation with a urologist or an oncologist
    B: Currently Receiving Adstiladrin: Approve for 3 months to allow a single dose to be administered 3 months after the most recent dose if BOTH of the following are met
    B.i Response status: Patient meets ONE: (a) Patient is in remission both on cytology and cystoscopic examination OR (b) Patient has cytology-positive, imaging- and cystoscopy-negative, recurrent or persistent disease
    B.ii Prescriber: The medication is prescribed by or in consultation with a urologist or an oncologist

    Coverage is recommended only when the patient meets the specific requirements described in the Recommended Authorization Criteria. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. The criteria will be updated as new published data become available; requests that do not meet the listed criteria should not be approved.

    Requests for Adstiladrin that fall outside the situations enumerated in the Recommended Authorization Criteria are considered not medically necessary and are not recommended for approval. No additional explicit "not medically necessary" conditions are provided beyond this exclusion statement; reviewers should deny requests that are not supported by the listed criteria.

    Coding and Eligibility

    No codes specified in documentmixed
    No codes listed
    Minimum age
    Minimum agePatient is ≥ 18 years of age
    Applies toAdults (all Aspirus Medicare Plans)
    RelevanceRequired for initial therapy authorization (part A.i)

    Authorization, Prescribing, and Operational Rules

    Prior Authorization

    Prior Authorization and Approval Duration

    Prior Authorization is recommended for Adstiladrin. Initial approvals are recommended for 4 months to allow two doses (given 3 months apart). Continuation (for patients currently receiving Adstiladrin) approvals are recommended for 3 months to allow a single dose 3 months after the most recent dose. All approvals are provided for the duration noted and extended approvals are allowed if the patient continues to meet the Criteria and Dosing. Requests for doses outside the established dosing documented in this policy will be reviewed on a case-by-case basis by a clinician (e.g., Medical Director or Pharmacist).

    • Initial approval: 4 months (allows 2 doses, 3 months apart)
    • Continuation approval: 3 months (allows single dose 3 months after most recent)
    • All approvals provided for the duration noted; extended approvals allowed if criteria continue to be met
    • Requests for non-standard doses considered case-by-case
    Step Therapy

    Step Therapy / Exceptions

    Key Definitions

    BCG-unresponsive NMIBC definition
    DefinitionHigh-risk BCG-unresponsive NMIBC: high-risk non‑muscle invasive bladder cancer not responding to prior BCG therapy; indication includes carcinoma in situ (CIS) with or without papillary tumors.
    Tumor presentations includedCIS (carcinoma in situ) OR Ta/T1 papillary tumors without CIS (per FDA indication and NCCN guidance).
    Use in ongoing therapyAlso applies to patients currently receiving Adstiladrin who meet response criteria (remission on cytology and cystoscopy or cytology-positive with imaging- and cystoscopy-negative recurrent/persistent disease).
    Prescriber requirementMedication must be prescribed by or in consultation with a urologist or an oncologist for patients meeting this definition.

    Background

    Adstiladrin (nadofaragene firadenovec) is a non-replicating adenoviral vector–based intravesical gene therapy approved for treatment of high-risk, BCG-unresponsive non‑muscle invasive bladder cancer (NMIBC) with carcinoma in situ, with or without papillary tumors, in adults. It is intended to be administered intravesically per the labeled regimen for this indication.

    Policy Changes

    2024-05-08revision

    Approval duration language updated: initial therapy approval set to 4 months (allowing 2 doses) and approvals provided 'for the duration noted'; added 3-month approval option for patients currently receiving Adstiladrin when prescribed by or in consultation with a urologist or oncologist.

    2023-06-14new_policy

    New policy created for Adstiladrin for Non‑Muscle Invasive Bladder Cancer (initial review date 2023-06-14).

    2023-11-15effective_date
    Policy Summary
    PayerAspirus Arise
    PolicyAdstiladrin (nadofaragene firadenovec) intravesical therapy — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeMaterial revisions to approval duration and prescriber requirement
    Effective DateNov 15, 2023
    Last ReviewApr 8, 2026
    Next Review DateApr 8, 2026
    Key ActionObtain prior authorization and ensure Adstiladrin is prescribed by or in consultation with a urologist or oncologist.
    SourceLink
    On This Page
    Recommended Authorization CriteriaCoding and EligibilityAuthorization, Prescribing, and Operational RulesKey DefinitionsBackgroundPolicy Changes

    No formal step therapy requirements are specified. However, requests for dosing outside the documented dosing schedule may be reviewed and considered on a case-by-case basis.

    • No step therapy required
    • Exceptions for doses outside documented dosing reviewed case-by-case
    Denial Risk

    Prescriber Requirements and Denial Triggers

    Adstiladrin must be prescribed by or in consultation with a urologist or oncologist. Prior Authorization is recommended. Requests that do not meet the Recommended Authorization Criteria (including indication, age, BCG‑unresponsive status, tumor type, or prescriber requirements) or requests for indications not listed in the criteria will not be recommended for approval.

    • Must be prescribed by or in consultation with a urologist or oncologist
    • Prior Authorization recommended
    • Denial triggers: requests not meeting the Recommended Authorization Criteria or for unlisted indications
    Latest

    Policy effective date recorded.